Gefitinib hydrochloride is a potent and selective oral EGFR tyrosine kinase inhibitor. It is widely used in oncology research to study its antitumor effects, including the inhibition of EGF-driven cell proliferation, induction of autophagy, and modulation of inflammation and fibrosis in both cellular and animal models.
